U.S. court finds Bayer Yaz contraceptive patent claims invalid
WASHINGTON, April 16
WASHINGTON, April 16 (Reuters) - A federal appeals court has ruled against Bayer AG, reversing a ruling by a lower court and finding that parts of a patent for the German drugmaker's Yaz oral contraceptive were invalid.
The U.S. Court of Appeals for the Federal Circuit ruled on Tuesday that a district court in Nevada had erred in finding two claims of a patent for the contraceptive to be "not invalid." It reversed the ruling.
The generic companies involved in the ruling, Watson Pharmaceuticals, which now goes by the name Actavis Inc, Sandoz Inc - the generic drug unit of Novartis - and Lupin Ltd, had argued that the patent was invalid and had told the U.S. Food and Drug Administration that they planned to bring out generic versions of the contraceptive.
The patent expires on June 30, 2014, the ruling said.
- Sierra Leone's chief Ebola doctor contracts the virus
- Gaza bloodshed deepens, airlines shun Israel |
- TransAsia Airways plane crashes in typhoon-hit Taiwan, killing 47
- South Korea ferry fugitive hid behind cabin wall, bags of cash at hand
- Two Ukrainian fighter jets shot down over rebel-held territory